Neuropathic Pain - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Neuropathic Pain - Pipeline Review, H1 2018’, provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain

The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects

The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuropathic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abide Therapeutics Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Adynxx Inc

Affectis Pharmaceuticals AG

Amneal Pharmaceuticals Inc

AnaBios Corp

Anavex Life Sciences Corp ...

AbbVie Inc

Abide Therapeutics Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Adynxx Inc

Affectis Pharmaceuticals AG

Amneal Pharmaceuticals Inc

AnaBios Corp

Anavex Life Sciences Corp

AngioChem Inc

Aptinyx Inc

Araim Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BCI Pharma SA

BCN Peptides SA

Biogen Inc

Bionomics Ltd

Can-Fite BioPharma Ltd

Cara Therapeutics Inc

Cavion LLC

Celgene Corp

Cellix Bio Pvt Ltd

Centrexion Therapeutics Corp

Cerecor Inc

CerSci Therapeutics Inc

Chromocell Corp

Circuit Therapeutics Inc

Colby Pharmaceutical Co

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Develco Pharma Schweiz AG

Dompe Farmaceutici SpA

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Evec Inc

Genecode AS

GL Pharm Tech Corp

Glialogix Inc

Grunenthal GmbH

GT Biopharma Inc

GW Pharmaceuticals Plc

Hydra Biosciences Inc

Immune Pharmaceuticals Inc

India Globalization Capital Inc

Intec Pharma Ltd

Integral Molecular Inc

Intellipharmaceutics International Inc

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

JT Pharmaceuticals Inc

Kancera AB

Knopp Biosciences LLC

Kolon Life Science Inc

Komipharm International Co Ltd

Lexicon Pharmaceuticals Inc

Lohocla Research Corp

Mapi Pharma Ltd

MD Biosciences GmbH

Medifron DBT Co Ltd

MEDRx Co Ltd

Merck & Co Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

Mundipharma International Ltd

Nanomerics Ltd

Neurim Pharmaceuticals Ltd

Neurocentrx Pharma Ltd

NeuroCycle Therapeutics GmbH

Neurodyn Life Sciences Inc

NeuroMax Ltd

NeurOp Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

NoNO Inc

Novartis AG

Novassay SA

OliX Pharmaceuticals Inc

Orexigen Therapeutics Inc

Patagonia Pharmaceuticals LLC

Pfizer Inc

Pharmaleads SA

Phosphagenics Ltd

Quartet Medicine Inc

RaQualia Pharma Inc

Re-Pharm Ltd

Relmada Therapeutics Inc

Revance Therapeutics Inc

Rottapharm Biotech Srl

Saniona AB

Shionogi & Co Ltd

Sollis Therapeutics Inc

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Toray Industries Inc

Trevena Inc

Vertex Pharmaceuticals Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Yooyoung Pharm Co Ltd

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Neuropathic Pain – Overview 10

Neuropathic Pain – Therapeutics Development 11

Neuropathic Pain – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 9

Neuropathic Pain – Overview 10

Neuropathic Pain – Therapeutics Development 11

Neuropathic Pain – Therapeutics Assessment 37

Neuropathic Pain – Companies Involved in Therapeutics Development 54

Neuropathic Pain – Drug Profiles 103

Neuropathic Pain – Dormant Projects 412

Neuropathic Pain – Discontinued Products 431

Neuropathic Pain – Product Development Milestones 436

Appendix 446

List of Tables

List of Tables

Number of Products under Development for Neuropathic Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Neuropathic Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Neuropathic Pain – Pipeline by AbbVie Inc, H1 2018

Neuropathic Pain – Pipeline by Abide Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Acadia Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Achelios Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Adynxx Inc, H1 2018

Neuropathic Pain – Pipeline by Affectis Pharmaceuticals AG, H1 2018

Neuropathic Pain – Pipeline by Amneal Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by AnaBios Corp, H1 2018

Neuropathic Pain – Pipeline by Anavex Life Sciences Corp, H1 2018

Neuropathic Pain – Pipeline by AngioChem Inc, H1 2018

Neuropathic Pain – Pipeline by Aptinyx Inc, H1 2018

Neuropathic Pain – Pipeline by Araim Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Arena Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Artelo Biosciences Inc, H1 2018

Neuropathic Pain – Pipeline by Asahi Kasei Pharma Corp, H1 2018

Neuropathic Pain – Pipeline by Astellas Pharma Inc, H1 2018

Neuropathic Pain – Pipeline by AstraZeneca Plc, H1 2018

Neuropathic Pain – Pipeline by Aucta Pharmaceuticals LLC, H1 2018

Neuropathic Pain – Pipeline by BCI Pharma SA, H1 2018

Neuropathic Pain – Pipeline by BCN Peptides SA, H1 2018

Neuropathic Pain – Pipeline by Biogen Inc, H1 2018

Neuropathic Pain – Pipeline by Bionomics Ltd, H1 2018

Neuropathic Pain – Pipeline by Can-Fite BioPharma Ltd, H1 2018

Neuropathic Pain – Pipeline by Cara Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Cavion LLC, H1 2018

Neuropathic Pain – Pipeline by Celgene Corp, H1 2018

Neuropathic Pain – Pipeline by Cellix Bio Pvt Ltd, H1 2018

Neuropathic Pain – Pipeline by Centrexion Therapeutics Corp, H1 2018

Neuropathic Pain – Pipeline by Cerecor Inc, H1 2018

Neuropathic Pain – Pipeline by CerSci Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Chromocell Corp, H1 2018

Neuropathic Pain – Pipeline by Circuit Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Colby Pharmaceutical Co, H1 2018

Neuropathic Pain – Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Develco Pharma Schweiz AG, H1 2018

Neuropathic Pain – Pipeline by Dompe Farmaceutici SpA, H1 2018

Neuropathic Pain – Pipeline by Eisai Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Eli Lilly and Co, H1 2018

Neuropathic Pain – Pipeline by Endece LLC, H1 2018

Neuropathic Pain – Pipeline by Evec Inc, H1 2018

Neuropathic Pain – Pipeline by Genecode AS, H1 2018

Neuropathic Pain – Pipeline by GL Pharm Tech Corp, H1 2018

Neuropathic Pain – Pipeline by Glialogix Inc, H1 2018

Neuropathic Pain – Pipeline by Grunenthal GmbH, H1 2018

Neuropathic Pain – Pipeline by GT Biopharma Inc, H1 2018

Neuropathic Pain – Pipeline by GW Pharmaceuticals Plc, H1 2018

Neuropathic Pain – Pipeline by Hydra Biosciences Inc, H1 2018

Neuropathic Pain – Pipeline by Immune Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by India Globalization Capital Inc, H1 2018

Neuropathic Pain – Pipeline by Intec Pharma Ltd, H1 2018

Neuropathic Pain – Pipeline by Integral Molecular Inc, H1 2018

Neuropathic Pain – Pipeline by Intellipharmaceutics International Inc, H1 2018

Neuropathic Pain – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2018

Neuropathic Pain – Pipeline by JT Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Kancera AB, H1 2018

Neuropathic Pain – Pipeline by Knopp Biosciences LLC, H1 2018

Neuropathic Pain – Pipeline by Kolon Life Science Inc, H1 2018

Neuropathic Pain – Pipeline by Komipharm International Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Lexicon Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Lohocla Research Corp, H1 2018

Neuropathic Pain – Pipeline by Mapi Pharma Ltd, H1 2018

Neuropathic Pain – Pipeline by MD Biosciences GmbH, H1 2018

Neuropathic Pain – Pipeline by Medifron DBT Co Ltd, H1 2018

Neuropathic Pain – Pipeline by MEDRx Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Merck & Co Inc, H1 2018

Neuropathic Pain – Pipeline by MindImmune Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Neuropathic Pain – Pipeline by Mundipharma International Ltd, H1 2018

Neuropathic Pain – Pipeline by Nanomerics Ltd, H1 2018

Neuropathic Pain – Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Neuropathic Pain – Pipeline by Neurocentrx Pharma Ltd, H1 2018

Neuropathic Pain – Pipeline by NeuroCycle Therapeutics GmbH, H1 2018

Neuropathic Pain – Pipeline by Neurodyn Life Sciences Inc, H1 2018

Neuropathic Pain – Pipeline by NeuroMax Ltd, H1 2018

Neuropathic Pain – Pipeline by NeurOp Inc, H1 2018

Neuropathic Pain – Pipeline by Newron Pharmaceuticals SpA, H1 2018

Neuropathic Pain – Pipeline by Nippon Chemiphar Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2018

Neuropathic Pain – Pipeline by NoNO Inc, H1 2018

Neuropathic Pain – Pipeline by Novartis AG, H1 2018

Neuropathic Pain – Pipeline by Novassay SA, H1 2018

Neuropathic Pain – Pipeline by OliX Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Orexigen Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Patagonia Pharmaceuticals LLC, H1 2018

Neuropathic Pain – Pipeline by Pfizer Inc, H1 2018

Neuropathic Pain – Pipeline by Pharmaleads SA, H1 2018

Neuropathic Pain – Pipeline by Phosphagenics Ltd, H1 2018

Neuropathic Pain – Pipeline by Quartet Medicine Inc, H1 2018

Neuropathic Pain – Pipeline by RaQualia Pharma Inc, H1 2018

Neuropathic Pain – Pipeline by Re-Pharm Ltd, H1 2018

Neuropathic Pain – Pipeline by Relmada Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Revance Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Rottapharm Biotech Srl, H1 2018

Neuropathic Pain – Pipeline by Saniona AB, H1 2018

Neuropathic Pain – Pipeline by Shionogi & Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Sollis Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Sorrento Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Sunovion Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Neuropathic Pain – Pipeline by Theranexus SAS, H1 2018

Neuropathic Pain – Pipeline by Toray Industries Inc, H1 2018

Neuropathic Pain – Pipeline by Trevena Inc, H1 2018

Neuropathic Pain – Pipeline by Vertex Pharmaceuticals Inc, H1 2018

Neuropathic Pain – Pipeline by Virobay Inc, H1 2018

Neuropathic Pain – Pipeline by VistaGen Therapeutics Inc, H1 2018

Neuropathic Pain – Pipeline by Vitality Biopharma Inc, H1 2018

Neuropathic Pain – Pipeline by Yooyoung Pharm Co Ltd, H1 2018

Neuropathic Pain – Pipeline by Yuhan Corp, H1 2018

Neuropathic Pain – Dormant Projects, H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..1), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..2), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..3), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..4), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..5), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..6), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..7), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..8), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..9), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..10), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..11), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..12), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..13), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..14), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..15), H1 2018

Neuropathic Pain – Dormant Projects, H1 2018 (Contd..16), H1 2018

Neuropathic Pain – Discontinued Products, H1 2018

Neuropathic Pain – Discontinued Products, H1 2018 (Contd..1), H1 2018

Neuropathic Pain – Discontinued Products, H1 2018 (Contd..2), H1 2018

Neuropathic Pain – Discontinued Products, H1 2018 (Contd..3), H1 2018

Neuropathic Pain – Discontinued Products, H1 2018 (Contd..4), H1 2018

List of Figures

List of Figures

Number of Products under Development for Neuropathic Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Neuropathic Pain, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports